Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced <scp>NSCLC</scp> Patients With Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations: A Multicenter, Phase <scp>II</scp> Trial

Authors

Institutions

Publication Details

Journal
Thoracic Cancer
Published
2025-08-01
DOI
https://doi.org/10.1111/1759-7714.70137
Citations
1
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial

Haohua Zhu, Haifeng Qin, Huiyang Shi, Jingyu Lu et al.
1 citations
Thoracic Cancer
Lung Cancer Treatments and Mutations
1.52
article

Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial

Haohua Zhu, Haifeng Qin, Huiyang Shi, Jingyu Lu, Xingsheng Hu, Yu Feng, Minglei Zhuo, Dongmei Lan, Junling Li, Mindy Wang, Yuankai Shi, Hongxia Zhang, Shi Jin, Jun Zhao, Guilan Dong, Kai Zhu, Zhong Dai, Meng Yang, Qingfang Shi
article en
1 citations

Abstract

No abstract available for this paper.
Thoracic CancerVol. 16(15)
Hengshui University (CN), Changzhi Medical College (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), China-Japan Friendship Hospital (CN), Peking University Cancer Hospital (CN), Tangshan People's Hospital (CN), Beijing Luhe Hospital Affiliated to Capital Medical University (CN), Beijing Hospital (CN), Cancer Hospital of Huanxing Chaoyang District Beijing (CN), Beijing Tsinghua Chang Gung Hospital (CN), Tsinghua University (CN)
Good health and well-being
Openalex Percentile: Top 15%
Lung Cancer Treatments and Mutations
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced <scp>NSCLC</scp> Patients With Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations: A Multicenter, Phase <scp>II</scp> Trial — Haohua Zhu, Haifeng Qin, et al. · Thoracic Cancer (2025) | TGRS Research Map | TGRS